Jorn Kaspers

519 total citations
10 papers, 428 citations indexed

About

Jorn Kaspers is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Jorn Kaspers has authored 10 papers receiving a total of 428 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Oncology and 5 papers in Genetics. Recurrent topics in Jorn Kaspers's work include Virus-based gene therapy research (5 papers), CAR-T cell therapy research (5 papers) and RNA Interference and Gene Delivery (4 papers). Jorn Kaspers is often cited by papers focused on Virus-based gene therapy research (5 papers), CAR-T cell therapy research (5 papers) and RNA Interference and Gene Delivery (4 papers). Jorn Kaspers collaborates with scholars based in Netherlands, United States and South Africa. Jorn Kaspers's co-authors include Lennart Holterman, Jaap Goudsmit, Menzo Havenga, Ronald Vogels, Angelique A. C. Lemckert, Remko van der Vlugt, Gert Gillissen, David Zuijdgeest, Dan H. Barouch and Jerome Custers and has published in prestigious journals such as Blood, Journal of Virology and Journal of Clinical Microbiology.

In The Last Decade

Jorn Kaspers

10 papers receiving 416 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jorn Kaspers Netherlands 8 264 226 150 133 100 10 428
Joanita Figueredo United States 10 475 1.8× 386 1.7× 138 0.9× 196 1.5× 92 0.9× 11 683
Marilyn Fernandez United States 9 308 1.2× 181 0.8× 139 0.9× 114 0.9× 201 2.0× 17 569
Rebecca A. Nace United States 16 487 1.8× 229 1.0× 250 1.7× 129 1.0× 84 0.8× 30 634
P Ng United States 7 196 0.7× 190 0.8× 72 0.5× 55 0.4× 134 1.3× 9 385
Markus Janke Germany 9 187 0.7× 133 0.6× 73 0.5× 59 0.4× 233 2.3× 11 438
Marlene Carmo United Kingdom 12 186 0.7× 193 0.9× 51 0.3× 76 0.6× 88 0.9× 18 328
W.A. Marasco United States 9 84 0.3× 181 0.8× 62 0.4× 63 0.5× 88 0.9× 9 350
Marko Marttila Sweden 7 506 1.9× 336 1.5× 206 1.4× 192 1.4× 90 0.9× 8 624
Yajin Ni United States 7 152 0.6× 182 0.8× 60 0.4× 45 0.3× 22 0.2× 10 289
Maureen Boyd Australia 11 204 0.8× 352 1.6× 74 0.5× 59 0.4× 66 0.7× 12 454

Countries citing papers authored by Jorn Kaspers

Since Specialization
Citations

This map shows the geographic impact of Jorn Kaspers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jorn Kaspers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jorn Kaspers more than expected).

Fields of papers citing papers by Jorn Kaspers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jorn Kaspers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jorn Kaspers. The network helps show where Jorn Kaspers may publish in the future.

Co-authorship network of co-authors of Jorn Kaspers

This figure shows the co-authorship network connecting the top 25 collaborators of Jorn Kaspers. A scholar is included among the top collaborators of Jorn Kaspers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jorn Kaspers. Jorn Kaspers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Kaspers, Jorn, Mihaela Popa, Alex Karlsson‐Parra, et al.. (2024). Vididencel, a Leukemia-Derived Dendritic Cell Vaccine, Acts Synergistically with Azacitidine/Venetoclax Treatment in a Preclinical AML Model. Blood. 144(Supplement 1). 2062–2062. 1 indexed citations
2.
Singh, Satwinder, Jorn Kaspers, Alwin Kamermans, et al.. (2021). 219 CD47 and phosphatidylserine contribute to the interaction between antigen presenting cells and the allogeneic cell-based relapse vaccine DCP-001. Regular and Young Investigator Award Abstracts. A232–A232. 1 indexed citations
3.
Kaspers, Jorn, Anneke W. Reurs, Saheli Sarkar, et al.. (2021). Transfer of Cellular Content from the Allogeneic Cell-Based Cancer Vaccine DCP-001 to Host Dendritic Cells Hinges on Phosphatidylserine and Is Enhanced by CD47 Blockade. Cells. 10(11). 3233–3233. 7 indexed citations
4.
Loosdrecht, Arjan A. van de, Sandra van Wetering, Saskia J. Santegoets, et al.. (2018). A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia. Cancer Immunology Immunotherapy. 67(10). 1505–1518. 71 indexed citations
5.
Havenga, Menzo, Lennart Holterman, Jorn Kaspers, et al.. (2007). Serum‐free transient protein production system based on adenoviral vector and PER.C6 technology: High yield and preserved bioactivity. Biotechnology and Bioengineering. 100(2). 273–283. 32 indexed citations
6.
Ophorst, Olga, Katarina Radošević, Krista Ouwehand, et al.. (2006). Expression and immunogenicity of the Plasmodium falciparum circumsporozoite protein: The role of GPI signal sequence. Vaccine. 25(8). 1426–1436. 10 indexed citations
7.
Thorner, Anna R., Ronald Vogels, Jorn Kaspers, et al.. (2006). Age Dependence of Adenovirus-Specific Neutralizing Antibody Titers in Individuals from Sub-Saharan Africa. Journal of Clinical Microbiology. 44(10). 3781–3783. 93 indexed citations
8.
Havenga, Menzo, Ronald Vogels, David Zuijdgeest, et al.. (2006). Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. Journal of General Virology. 87(8). 2135–2143. 78 indexed citations
9.
Kaspers, Jorn, et al.. (2004). Retroviral hybrid LTR vector strategy: functional analysis of LTR elements and generation of endothelial cell specificity. Gene Therapy. 11(9). 775–783. 13 indexed citations
10.
Holterman, Lennart, Ronald Vogels, Remko van der Vlugt, et al.. (2004). Novel Replication-Incompetent Vector Derived from Adenovirus Type 11 (Ad11) for Vaccination and Gene Therapy: Low Seroprevalence and Non-Cross-Reactivity with Ad5. Journal of Virology. 78(23). 13207–13215. 122 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joanita Figueredo Breakdown of academic impact, for papers by Marilyn Fernandez Breakdown of academic impact, for papers by Rebecca A. Nace Breakdown of academic impact, for papers by P Ng Breakdown of academic impact, for papers by Markus Janke Breakdown of academic impact, for papers by Marlene Carmo Breakdown of academic impact, for papers by W.A. Marasco Breakdown of academic impact, for papers by Marko Marttila Breakdown of academic impact, for papers by Yajin Ni Breakdown of academic impact, for papers by Maureen Boyd
Rankless by CCL
2026